IMMUNOVIA AB NPV revenue breakdown overview

IMMUNOVIA AB NPV revenue for the last year amounted to 1.57 M SEK, the most of which — 1.57 M SEK — came from its highest performing source at the moment, Non-invasive Blood Tests, the year earlier bringing 1.15 M SEK. The greatest contribution to the revenue figure was made by United States — last year it brought IMMUNOVIA AB NPV 800.00 k SEK, and the year before that — 468.00 k SEK.